Program
VS-01
A development code. Also written as “VS-01 on top of SOC” and “VS-01 on top of SOC (Active Treatment Group)”.
Its studies are mostly in Acute-On-Chronic Liver Failure · Hepatic Encephalopathy, led by Genfit.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genfit | 20 open or running | phase 2since Jun 2, 2023 | Jun 2, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 2, 2023First study: phase 2 study in Acute-On-Chronic Liver FailureFirst studyNCT05900050 · 15 enrolled · United States, Belgium, France and more
- May 7, 2025Phase 2 study in Hepatic EncephalopathyNCT06987968 · 3 enrolled · United States, France, Georgia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06987968Hepatic Encephalopathy · United States, France, Georgia | 2 | Terminated | Sep 8, 2025 | 3 |
| NCT05900050Acute-On-Chronic Liver Failure · United States, Belgium, France and more | 2 | Terminated | Oct 15, 2025 | 15 |
How it is read
Names in the registry
- “VS-01 on top of SOC”, 1 entry
- “VS-01 on top of SOC (Active Treatment Group)”, 1 entry
Codes read as this program: VS01.
Conditions, from the studies’ own filings
- Acute-On-Chronic Liver Failure, 1 study
- Hepatic Encephalopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.